JMS CO., LTD.
http://www.jms.cc/
Company Code No. 7702

Financial Statements
for the 2nd quarter of fiscal year ending March 31, 2014
(From Apr. 1, 2013 to Sep. 30, 2013)

Summary of consolidated results

The assessment figures described on this report are based on available information
at this moment, including uncertain data. Actual results may be different from the figures.

1

Highlights in Business Results
4th straight year of increased sales, but decreased profit for first half of the FYE Mar. 2014

Sales: JPY 25,714 million, up 7.4%

( %: compared with previous year)[Japan]‐Continued growth in the sales of Infusion / Transfusion‐related products and medical gloves

Sales[Overseas]‐Positive sales of apheresis kits for the OEM business‐Continued solid sales of safety scalp vein sets
‐Influence of exchange conversion by the weak yen

Operating income: JPY 196 million (down 80.3%),
Ordinary income: JPY 444 million (down 62.5%), Net income: JPY 200 million (down 71.7%)
Profit‐Increase of labor costs as well as selling expenses such as freight and fees etc.

Revision of consolidated business forecast for the FY ending Mar 31. 2014
Because of the above mentioned reason, consolidated business forecast for the fiscal year ending
March 31, 2014 has been revised2

Consolidated Business Results
4th straight year of increased sales, but decreased profit
Apr. ‐ Sep. 2012

Year‐over‐Year

Apr. ‐ Sep. 2013
Previous
Forecast

Results(unit: JPY million)

Results

Diff. fromforecast

23,94625,000Operating Income

994

1,000

196 (80.3%) (80.4%)

Ordinary Income

1,185

1,050

444 (62.5%) (57.7%)

709

650

200 (71.7%) (69.2%)

JPY 16.45

JPY 13.33

SalesNet IncomeNet Income per share

25,714

JPY 4.12

7.4%

‐‐‐

Exchange Rate (average during period)

2.9%

‐‐‐
(unit: JPY)

US Dollar

79.41

95.00

98.85

‐‐‐

‐‐‐

Euro

103.45120.00125.50‐‐‐‐‐‐Singapore Dollar

63.23

75.00

78.55

‐‐‐

‐‐‐

3

Sales by segment (geographical area)
Apr. – Sep. 2012

Apr. – Sep. 2013

(unit: JPY million)

20,00019,737 19,381
18,00016,00019,737

Sales
Sales incl.
incl. internalinternal transaction
transaction

19,381

17,38917,389 17,367
17,367

Sales
Sales forfor third
third party
party

8,000
8,5466,000
6,916
4,000
2,000

3,127

4,180

1,534 1,724
4630Japan

Southeast Asia

646

China

1,253 1,383 1,109 1,367
1,251 1,383 1,109 1,367
Germany

United States

604604

770
770

Others4

Profit by segment (geographical area)
Apr. – Sep. 2012

Apr. – Sep. 2013

(unit: JPY million)

800

743

700
600
500
400
300
200

254
188
74

100(14)17112

67111(81)81
150(100)
Japan

Southeast Asia

China

Germany

United States

Others5

Summary by segment (geographical area)%: year‐over‐year

Sales
Ordinary IncomeJapan

SoutheastAsia

China

19,381 JPY mil.

(1.8%)

188 JPY mil.

(74.7%)‐Continued growth in the sales of Infusion / Transfusion‐
related products and medical gloves was offset by thesales drop of hemodialysis machine and its ancillaryequipments

Sales

8,546 JPY mil.

23.6%

Ordinary Income(14) JPY mil.

－Infusion set with aneedleless access port,“PLANECTA”
Infusion set is used for drug administration to ahuman body. “PLANECTA” is a needleless access
port, allowing connections without a needle, which
offers minimized infection risk to patients andmedical staff by reducing the risk of contamination
coming from blood or solution, and preventing
needle‐stick accidents.

‐Despite the stagnant sales of hemodialysis bloodtubing sets for Japan, apheresis kits for the OEM
customer boosted net sales

Sales

1,742 JPY mil.

12.3%

Ordinary Income(81) JPY mil.

－‐Despite the sales drop of infusion sets for Japan,
continued growth in the sales of AV fistula needles
for Western and domestic markets raised net sales

Medical Gloves(Surgical, Examination and Treatment Use)
Gloves are used for various medical fields suchas surgery and examination etc. Synthetic latexgloves for medical professionals with latex
allergies are on our product lineup as well as
natural latex gloves.

6Summary by segment (geographical area)%: year‐over‐year

Sales
Ordinary Income
Germany

10.3%

112 JPY mil.

51.8%

‐Strong sales of blood purification‐related
products for domestic market raised net sales

Sales
Ordinary Income
United States

1,383 JPY mil.

1,367 JPY mil.

23.3%

AV Fistula Needle

111 JPY mil.

63.8%

AV fistula needle is for pulling blood from apatient during a dialysis therapy.

‐Continued solid sales of safety scalp vein sets forNorth America boosted net sales

Sales

770 JPY mil.

27.5%

Ordinary Income

15 JPY mil.

(80.7%)

Safety Scalp Vein setOthers

Safety scalp vein set is an injection needle withtube for infusion and blood sampling. It has asafety function to prevent medical staff from
accidental needle sticks.

7

Sales by Business Segment
Apr. – Sep. 2012

(unit: JPY million)

Apr. – Sep. 2013

14,00012,00010,00012,474

8,000
6,000
4,000

11,118+12.
+1,355

7,852
2%

7,908

+55 +0.7%+123 +5.7%

2,000
2,163

2,287+107 +5.3%

2,040

Dialysis

General MedicalSupplies

6. 3%7708962,148

0Infusion andTransfusion+1+12 5

Cardiovascular

Others8

Sales by Segment (Customer's Location)
Apr. – Sep. 2012

Apr. – Sep. 2013

(unit: JPY million)

20,00017,104 17,193

Others 3%

Asia・Oceania 13%

16,000Europe 8%

Apr. – Sep.
2013

12,000
North America 9%8,000Japan 67%

3,247

4,000
1,821

2,383

1,815

2,063

2,449
755

827

0
Japan

North America

EuropeAsia・Oceania

Others9

Selling, General and Admin. Expenses(unit: JPY million)(unit: JPY million)6,371
6,000

5,859

24.5%

24.8%

4,00020%
SGA ratio

＋0.3%

2,000

10%

Apr. ‐ Sep.
2013

Labor Cost

2,621

2,797

175

6.7%

Transport

689

790

101

14.7%

R&D

610

585(25)(4.1%)

Depreciation

167

196

28

17.3%

1,770

2,001

231

13.1%

5,859

6,371

511

8.7%

OthersTotal

0Year‐over‐Year

Apr. ‐ Sep.
2012

30%

Diff.

0%
Apr. ‐ Sep.
2012

Apr. ‐ Sep.
2013
10Ordinary Income: Compared with the previous year
Minus factor
Ordinary
IncomeApr.‐Sep. 2012

Plus factor

1,185（345）

Ordinary income decreasedJPY 741 million

Decrease of
Gross Profit（285）

Increase of SGA（7）

Decrease of
Non‐operating profit(103)
OrdinaryIncome
Apr.‐Sep. 2013

(unit: JPY million)

Impact of
Exchange rate

444
The underlined figures exclude impact of exchange rate.
1111

Forecast for FYE Mar. 2014
(unit: JPY million)FYE Mar. 2013
ResultFYE Mar. 2014 Forecast
Previous
Forecast

AmountChangedNew
Forecast

Sales

49,06851,50052,5001.9%

Operating Income

1,594

2,100

1,000(52.4%)

Ordinary Income

1,879

2,300

1,200(47.8%)

Net Profit

1,277

1,400600(57.1%)

JYP 29.41

JYP 28.70

JYP 12.30‐‐‐

Net profit per hare

Exchange Rate (average during period)(unit: JPY)

US Dollar

83.10

95.00

97.00

---Euro102.63120.00127.00---Singapore Dollar

66.88

75.00

79.00

---

Consolidated business forecast for the fiscal year ending March 31, 2014 has been revised, due tothe above mentioned business results.
12Topics< Apr. – Sep. 2013 >‐ Date shows the press release date.

‐ Launching new product “PEKO PANDA”, Tongue muscle
training tool.
Sep. 27, 2013
Tongue muscle training tool
“PEKO PANDA”‐ Launching new product “JPAD CU‐SP1”, Automated external defibrillator.
Sep. 20, 2013
Automated external defibrillator“JPAD CU‐SP1”‐ Launching new product “LEG SCIENCE MAI”, Medical elastic stockings.
Jun. 27, 201313

The Bridge to Good Health CareJMS will continue its activities for contributing to medicalcare, with our corporate philosophy “Patient comes first”.
JMS continue to dedicate effort to creating happiness forpatients, their families and medical staff in line with its
basic principle, “delivering goods and services for ourcustomer’s satisfaction ”.
Thank you very much for your patronage and support.

14